Humanised monoclonal antibody therapy for rheumatoid arthritis.
Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than...
Asıl Yazarlar: | Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
1992
|
Benzer Materyaller
-
HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
Yazar:: Isaacs, J, ve diğerleri
Baskı/Yayın Bilgisi: (1992) -
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
Yazar:: Isaacs, J, ve diğerleri
Baskı/Yayın Bilgisi: (2004) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
Yazar:: Isaacs, J, ve diğerleri
Baskı/Yayın Bilgisi: (2005) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
Yazar:: Isaacs, J, ve diğerleri
Baskı/Yayın Bilgisi: (2005) -
Humanized monoclonal antibody treatment in rheumatoid arthritis.
Yazar:: Kyle, V, ve diğerleri
Baskı/Yayın Bilgisi: (1991)